BioWorld

May 19, 2004

Celltech Agrees To Buyout By UCB For $2.7B In Cash

LONDON - Celltech Group plc, the UK's largest biotechnology company, has agreed to be taken over by UCB SA, of Brussels, Belgium, in an all-cash deal that values Celltech at about £1.5 billion (US$2.7 billion). (BioWorld Today) Read More

Chiron's Failed Sepsis Drug Taking On CAP In Phase III

FDA: Critical Path Initiative' Sharpens Drug Development

Pozen Starts Phase III Migraine Program, Hits $15M Milestone

Neose Offering Brings In $34M For EPO, G-CSF Development

Panacos Attracts $18.3M Round To Fund HIV Drug Development

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Jan 20, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 20, 2026.

Illustration of human body surrounded by DNA, cell and drug icons

Cell/gene therapy sector now sustainable; China competition mounting

BioWorld

There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...

Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal

BioWorld

With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...

Illustration of magnifying glass inspecting brain

Neurotrimin unveiled as marker in intellectual disability

BioWorld Science

Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...